Top Markets
Coin of the day
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Hisse Senetlerindeki Sıralama #40865
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Hisse Fiyatı
$0.0006
Son senkronizasyon: 2025-06-30
Piyasa Değeri
$69.91K
Değişim (1 gün)
-88.46%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Immatics biotechnologies GmbH (IMTXW)

Kategori

B piyasa değeri ile IMTXW fiyatı
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
IMTXW
$0.0006
Piyasa Değeri Immatics biotechnologies GmbH(IMTXW)
Piyasa Değeri: $69.91K
August 2026 itibarıyla Immatics biotechnologies GmbH şirketinin piyasa değeri $69.91K. Bu, verilerimize göre Immatics biotechnologies GmbH şirketini dünyanın en değerli 40865th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
Immatics biotechnologies GmbH piyasa değeri geçmişi (2020 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında IMTXW
IMTXW’in Fiyatı B Varlığı B’nin Piyasa Değeri Sonuçlar
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$46,710.30 $69.91K
$5.442T +7,785,049,179.22%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$38,308.02 $69.91K
$4.463T +6,384,669,773.10%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$35,843.15 $69.91K
$4.176T +5,973,858,213.68%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$31,581.37 $69.91K
$3.680T +5,263,561,852.38%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$24,625.18 $69.91K
$2.869T +4,104,196,803.14%